Abbvie Inc (ABBV)

$213.76 +4.35 (2.08%)
Market Cap 371.72B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 20.68
Forward PE 14.72
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 7,220,200
Avg Vol 6,850,402
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 63%
Beta 0.32
Analysts Strong Sell
Price Target $251.17

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Mike22332233
Mike22332233 May. 19 at 11:56 PM
$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!
1 · Reply
SellasgpsCurativeBAT12
SellasgpsCurativeBAT12 May. 19 at 10:05 PM
$ABBV $ALPMY $NVS $SLS Trading will be halted before any Deal or Data PR! 🙏✌️❤️‍🩹
0 · Reply
TalkMarkets
TalkMarkets May. 19 at 9:49 PM
Dividend Growth Stocks: The Bedrock Of Your Retirement Portfolio $ABBV https://talkmarkets.com/article/dividend-growth-stocks-the-bedrock-of-your-retirement-portfolio-1779227312
0 · Reply
SellasgpsCurativeBAT12
SellasgpsCurativeBAT12 May. 19 at 8:47 PM
$SLS $ABBV $NVS $ALPMY These 4 companies drugs are going to be Obsolete after GPS FDA approval: AbbVie and Genentech: Venclexta (venetoclax) Astellas Pharma: Xospata (gilteritinib) Novartis Pharmaceuticals: Rydapt (midostaurin) Bristol Myers Squibb: Onureg Combined Sellas Platform can treat entire AML from start to finish and will make $10 Billion dollar blockbusters Obsolete. ABBV and Merck will be the biggest looser of the imminent bidding war if they don’t make a move pre- GPS Regal Pivotal Registrational Phase 3 study. SLS GPS will dethrone Merck’s Keytruda as # 1 selling drug on the planet with peek sales of $35 Billion + Mark this post and frame it, Bidding war= $280.00+ 🙏✌️❤️‍🩹
0 · Reply
CaymanStyleBeef
CaymanStyleBeef May. 19 at 3:14 PM
$ABBV $CELH $NKE $RACE good for a red day...diversified gains...stack um up 🤣
0 · Reply
Blockwave1
Blockwave1 May. 19 at 3:14 PM
$ABBV 🩺 $222.5 22 MAY 26 (W) CALL 100 $0.23 ➡️ $0.53 130% GAINER! More wins🔥
1 · Reply
Amscru80
Amscru80 May. 19 at 2:44 PM
$ICCM this is a real gem, news today!! 💎 $SLS $ABBV $PFE $LLY
0 · Reply
Blockwave1
Blockwave1 May. 19 at 2:20 PM
$0.37 on $ABBV here! 60% return! 🔥
0 · Reply
Blockwave1
Blockwave1 May. 19 at 2:18 PM
ADDED HEAVY!!🚨 $ABBV 22 MAY 26 $222.5 CALL $0.23 RELATIVE STRENGTH + SECTOR SENTIMENT + ADDING HEAVY + HIGH CONFIDENCE
0 · Reply
Blockwave1
Blockwave1 May. 19 at 2:17 PM
$ABBV 22 MAY 26 $222.5 CALL $0.23 RELATIVE STRENGTH + SECTOR SENTIMENT + ADDING HEAVY + HIGH CONFIDENCE
0 · Reply
Latest News on ABBV
AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 13 days ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 14 days ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 18 days ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 18 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 19 days ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 19 days ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 20 days ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:50 AM EDT - 20 days ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 20 days ago

AbbVie Reports First-Quarter 2026 Financial Results

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 8:00 AM EDT - 21 days ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 28, 2026, 7:00 AM EDT - 21 days ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 27, 2026, 8:05 AM EDT - 22 days ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 26 days ago

US FDA declines to approve AbbVie's wrinkle treatment

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 23, 2026, 4:05 PM EDT - 26 days ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:59 PM EDT - 27 days ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 22, 2026, 12:02 PM EDT - 27 days ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 20, 2026, 2:30 AM EDT - 4 weeks ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 5 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 13, 2026, 2:24 AM EDT - 5 weeks ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 12, 2026, 7:15 AM EDT - 5 weeks ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 1:38 PM EDT - 5 weeks ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 8, 2026, 8:00 AM EDT - 5 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:53 AM EDT - 6 weeks ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 7, 2026, 9:00 AM EDT - 6 weeks ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Swiss industry body says US tariffs on pharmaceuticals will harm patients

Apr 3, 2026, 11:08 AM EDT - 6 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Apr 2, 2026, 5:34 PM EDT - 6 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

Apr 2, 2026, 5:33 PM EDT - 6 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

Apr 2, 2026, 3:29 PM EDT - 6 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Global pharma companies that have publicly announced Trump drug pricing agreements

Apr 2, 2026, 2:59 PM EDT - 6 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:05 AM EDT - 7 weeks ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 31, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 27, 2026, 10:00 AM EDT - 7 weeks ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 24, 2026, 8:00 AM EDT - 2 months ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Mar 20, 2026, 12:11 PM EDT - 2 months ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 2 months ago

Buy Or Fear AbbVie Stock At $210?

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 19, 2026, 3:00 AM EDT - 2 months ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 13, 2026, 9:00 AM EDT - 2 months ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 3, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Mar 2, 2026, 8:30 AM EST - 2 months ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 3 months ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23, 2026, 12:03 PM EST - 3 months ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Feb 23, 2026, 11:00 AM EST - 3 months ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Feb 20, 2026, 2:00 AM EST - 3 months ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

AbbVie Declares Quarterly Dividend

Feb 19, 2026, 9:37 AM EST - 3 months ago

AbbVie Declares Quarterly Dividend

AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 6:49 PM EST - 3 months ago

AbbVie sues US health agency over Botox price controls

Abbvie sues US health agency over Botox

Feb 11, 2026, 5:13 PM EST - 3 months ago

Abbvie sues US health agency over Botox

AbbVie Revenue Rises on Immunology Growth

Feb 4, 2026, 8:34 AM EST - 3 months ago

AbbVie Revenue Rises on Immunology Growth

Mike22332233
Mike22332233 May. 19 at 11:56 PM
$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!
1 · Reply
SellasgpsCurativeBAT12
SellasgpsCurativeBAT12 May. 19 at 10:05 PM
$ABBV $ALPMY $NVS $SLS Trading will be halted before any Deal or Data PR! 🙏✌️❤️‍🩹
0 · Reply
TalkMarkets
TalkMarkets May. 19 at 9:49 PM
Dividend Growth Stocks: The Bedrock Of Your Retirement Portfolio $ABBV https://talkmarkets.com/article/dividend-growth-stocks-the-bedrock-of-your-retirement-portfolio-1779227312
0 · Reply
SellasgpsCurativeBAT12
SellasgpsCurativeBAT12 May. 19 at 8:47 PM
$SLS $ABBV $NVS $ALPMY These 4 companies drugs are going to be Obsolete after GPS FDA approval: AbbVie and Genentech: Venclexta (venetoclax) Astellas Pharma: Xospata (gilteritinib) Novartis Pharmaceuticals: Rydapt (midostaurin) Bristol Myers Squibb: Onureg Combined Sellas Platform can treat entire AML from start to finish and will make $10 Billion dollar blockbusters Obsolete. ABBV and Merck will be the biggest looser of the imminent bidding war if they don’t make a move pre- GPS Regal Pivotal Registrational Phase 3 study. SLS GPS will dethrone Merck’s Keytruda as # 1 selling drug on the planet with peek sales of $35 Billion + Mark this post and frame it, Bidding war= $280.00+ 🙏✌️❤️‍🩹
0 · Reply
CaymanStyleBeef
CaymanStyleBeef May. 19 at 3:14 PM
$ABBV $CELH $NKE $RACE good for a red day...diversified gains...stack um up 🤣
0 · Reply
Blockwave1
Blockwave1 May. 19 at 3:14 PM
$ABBV 🩺 $222.5 22 MAY 26 (W) CALL 100 $0.23 ➡️ $0.53 130% GAINER! More wins🔥
1 · Reply
Amscru80
Amscru80 May. 19 at 2:44 PM
$ICCM this is a real gem, news today!! 💎 $SLS $ABBV $PFE $LLY
0 · Reply
Blockwave1
Blockwave1 May. 19 at 2:20 PM
$0.37 on $ABBV here! 60% return! 🔥
0 · Reply
Blockwave1
Blockwave1 May. 19 at 2:18 PM
ADDED HEAVY!!🚨 $ABBV 22 MAY 26 $222.5 CALL $0.23 RELATIVE STRENGTH + SECTOR SENTIMENT + ADDING HEAVY + HIGH CONFIDENCE
0 · Reply
Blockwave1
Blockwave1 May. 19 at 2:17 PM
$ABBV 22 MAY 26 $222.5 CALL $0.23 RELATIVE STRENGTH + SECTOR SENTIMENT + ADDING HEAVY + HIGH CONFIDENCE
0 · Reply
Amscru80
Amscru80 May. 19 at 2:03 PM
$ICCM buy now or cry later, with great news!!! 🚀🚀🚀 $SLS $LLY $ABBV $CGON
0 · Reply
Mike22332233
Mike22332233 May. 19 at 12:04 PM
$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!
2 · Reply
Mike22332233
Mike22332233 May. 19 at 12:36 AM
$SLS SPOT ON — and exactly what many of us have been saying for over a year now !!! … and much of this is what I based my BO final price in a bidding war (between $MRK, $PHE, $ABBV) to be $222 !!!! FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 18 at 5:57 PM
$SLS -- Is it $PFE $ABBV or $MRK
1 · Reply
SellasgpsCurativeBAT12
SellasgpsCurativeBAT12 May. 18 at 4:09 PM
$ABBV $IMGN $LLY $PFE $SLS Volume just crossed 5 million shares in first 2.5 hours of trading. Big Institutional funds gobbling up every loose share before the next PR Hits. ✌️❤️‍🩹🙏
0 · Reply
SellasgpsCurativeBAT12
SellasgpsCurativeBAT12 May. 18 at 3:43 PM
$SLS $ABBV $PFE $MRK AbbVie has already terminated all Viale studies in anticipation of the GPS Regal Pivotal Registrational phase 3 Paradigm shifting data. AbbVie will be the biggest looser if another big pharmaceutical picks up 13 FTE Sellas First. ✌️❤️‍🩹🙏
2 · Reply
SellasgpsCurativeBAT12
SellasgpsCurativeBAT12 May. 18 at 3:36 PM
$IMGN $LLY $PFE $SLS $ABBV AbbVie will make a move before the bidding war starts. I see them coming before the GPS Regal Pivotal Registrational phase 3 data comes out. Ventoclax is $1.9 Billion dollar annual blockbuster for AbbVie. Merck has already done multiple studies with SLS GPS+ Keytruda, with Keytruda patent expiring in 2028. Merck will be part of the bidding war unless AbbVie picks them up pre data read out! ✌️❤️‍🩹🙏
1 · Reply
trenddetector
trenddetector May. 18 at 3:14 PM
$ABBV Blood cancers like leukemia and lymphoma come with a steep learning curve — new terms, new drugs, new decisions, all at once. If someone you know is newly diagnosed and trying to make sense of treatments like Venclexta or Imbruvica, YourCancerPath.com can help them get oriented fast. It's free, anonymous, and built for patients — not doctors. No jargon, no sales pitch, just real guidance. Please share this today with anyone in your life who's in the middle of a cancer fight. They deserve a clearer path. 🔗 YourCancerPath.com #leukemia #lymphoma #ABBV #YourCancerPath
0 · Reply
CapitalMonk
CapitalMonk May. 18 at 3:09 PM
$ABBV Price: $210.49 (+0.05%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.76% RSI: 67.7 | Momentum: Moderate Volume: -86.5% vs avg Volatility: 1.56% Support: $190.75 | Resistance: $214.92 Sourch: http://marketbaubles.com/
0 · Reply
Mike22332233
Mike22332233 May. 18 at 12:11 PM
$SLS Some think $40 Bil BO is silly ... really, FOR AN EFFECTIVE CURE FOR CANCER !!! ... and then across 20 other cancers with WT1 !!! Add in the SLS001 platform!!! ... KEYTRUDA has sales of $34 Bil per year and does NOT cure anything ... We will see how silly it is when $MRK, $ABBV and $PFE are in a bidding war to buy out $SLS ... SLS is the Single BEST asymmetrical investment idea in my over 40 years investing ... ALL my profits from every other Special Situation Stock I have found (see my other posts) have been plowed back into more SLS ... If you agree with what I will say, then LIKE this and FOLLOW me 👉 @Mike22332233 ...
1 · Reply
Mike22332233
Mike22332233 May. 18 at 11:55 AM
$SLS PART 2 of 2 .. Even with the BAT arm at 14.7 mOS which is twice as long as expected … EFFECTIVELY, those getting GPS that had an immune response (80% of them) ARE NOT PASSING AWAY!!! ... GAME CHANGING FOR CANCER !!! When the trial ends at the 80th event, I believe you would have ALL 63 in the BAT Control arm passed away, AND ONLY 17 OF THE 63 GPS PATIENTS PASSED AWAY … 46 of the 63 will be alive and living into their 4th yr and some into their 5th year…. This has EFFECTIVELY STOPPED CANCER FROM KILLING THEM IN THIS TYPE OF CANCER !! ... There are an additional 20 or so Cancers with the WT1 within them … as I said before, likely $ABBV or $MEK or $PFE doing a BUY OUT WITHIN 3 months of the readout, and my MAXIMUM PRICE OF $150 to $175 (a $30 to $35 Billion valuation) for the BO may very well be much too low if the HR is GAME-CHANGING at 0.27-0.35 ... if so, expect a bidding war and final BO at $222 !!! ... If you agree then LIKE this and FOLLOW me 👉 @Mike22332233
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 17 at 9:10 PM
$SLS IDMC Unblinded actual MOS and IR Data from the Interim Analysis 60th Event - told all industry participants Gps works. Industry Participants: $ABBV $RHHBY Know its not BAT AzaVEN 39 funds invested in SLS, now 160 - the market is telling anyone paying attention.\ the IDMC unblinded Cctual survival data and Immune Response data, at the 60th event, that told market participants who are Familiar and knowledgeable -- 80% Immune Response Rates .. .. is confirmed Efficacy .... MOS survival for all Pooled Patients NYM > 13.5 months for Control + patients on Gps Immunotherapy was 2x longer than Known OS for Control.
0 · Reply